BRAF and breast carcinoma: In addition to the HER2-breast cancer (#5) and BRAF–melanoma (#12) co-modules, other cancer-related co-modules were selected, such as those representing the hypermutated phenotype (#3) and responders to receptor tyrosine kinase inhibitors (#28) (Table S2).